Novartis

Novartis
Bâle, Nord Ouest de la Suisse
Web: Novartis
Lieu: Bâle
Domaine: Médecine/Pharmacologie
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Médecine 22.1
Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform -   Lutathera (lutetium Lu 177 dotatate), with a US PDUFA date of January 26, creates anticipation for NET portfolio expansion -   Radioligand therapy (RLT) pipeline includes 177Lu-PSMA-R2 entering Phase 1/2 study
Médecine 18.1

Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon strateg

Médecine 16.1

Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matc

Médecine 11.1

Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development org

Médecine 17.1

Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy -   EMA granted accele

Médecine 16.1

Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data suppo

Médecine 9.1

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS) EXCEED is the first head-to-head superiority trial versus Humira * in psor



website preview

Link

Medicine and Life Sciences